BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

More Money? Vasella May be a Novartis AG (NVS) Consultant


2/22/2013 7:15:07 AM

Fresh from an embarrassment over a widely criticized non-compete deal that was scrapped this week, the Novartis board may now offer a consulting contract to Dan Vasella, Bloomberg News reports. What is not clear is whether Vasella, who had offered to donate the $72 million he was to have received from the non-compete, will do the same with the proceeeds from a consulting gig. The non-compete caused considerable ruckus for the drugmaker, which had not publicly disclosed the six-year agreement with Vasella and has been regularly chastised for the compensation awarded the departing exeutive. The agreement angered shareholders and has figured prominently in an upcoming national referendum in Switzerland, wher Novartis (NVS) is headquartered, that would give citizens a chance to decide whether shareholders should have more say in executive compensation. Had the non-compete deal not been leaked, “no one would have known about the gigantic sums you were talking about,” Dominique Biedermann, executive director of Ethos, a foundation that advises institutional investors on corporate governance issues, said at the Novartis shareholder meeting.

Read at Pharmalot
Read at Reuters
Read at Financial Times

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES